BANK OF MONTREAL /CAN/ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$913,000
-17.8%
359,381
-5.2%
0.00%
-100.0%
Q2 2021$1,111,000
+58.5%
379,081
+36.9%
0.00%
Q1 2021$701,000
+8662.5%
276,988
+6774.9%
0.00%
Q4 2020$8,000
+100.0%
4,0290.0%0.00%
Q3 2020$4,000
+33.3%
4,0290.0%0.00%
Q2 2020$3,0000.0%4,0290.0%0.00%
Q1 2020$3,000
-81.2%
4,029
-77.3%
0.00%
Q4 2019$16,000
+23.1%
17,734
+30.8%
0.00%
Q3 2019$13,00013,5590.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders